Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 24;29(1):68–76. doi: 10.3390/curroncol29010006

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

(A) Anti-spike Antibody Concentrations in Healthy Controls and Cancer Patients Following Two Doses of SARS-CoV-2 Vaccine. (B) Anti-spike Antibody Levels in Cancer Patients On and Off Treatment. (C) Frequency of Seroconversion Rate in Healthy Patients and Cancer Patients According to 35.2 BAU/mL cutoff. p-values as determined by (A) Tukey test against healthy controls, (B) Tukey test against off treatment group, and (C) Chi-square test against healthy controls. HC: healthy controls; ST: solid tumor; HM: hematological malignancy.

(A) Anti-spike Antibody Concentrations in Healthy Controls and Cancer Patients Following Two Doses of SARS-CoV-2 Vaccine. (B) Anti-spike Antibody Levels in Cancer Patients On and Off Treatment. (C) Frequency of Seroconversion Rate in Healthy Patients and Cancer Patients According to 35.2 BAU/mL cutoff. p-values as determined by (A) Tukey test against healthy controls, (B) Tukey test against off treatment group, and (C) Chi-square test against healthy controls. HC: healthy controls; ST: solid tumor; HM: hematological malignancy.